Evidence map›Paper›PMID 27705934›Full record

ArticleOncotarget2017

Notch1 promotes vasculogenic mimicry in hepatocellular carcinoma by inducing EMT signaling.

Chen Jue, Cui Lin, Zhang Zhisheng, Qian Yayun, Jin Feng, Zhao Min, Wang Haibo, Shi Youyang, Tadashi Hisamitsu, Ishikawa Shintaro and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The role of kinesin superfamily proteins in hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Chen JueInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Cui LinDepartment of Oncology, The Second Peoples Hospital of Taizhou Affiliated to Yangzhou University, Taizhou, Jiangsu, China.
Zhang ZhishengDepartment of Oncology, The Second Peoples Hospital of Taizhou Affiliated to Yangzhou University, Taizhou, Jiangsu, China.
Qian YayunInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Jin FengInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Zhao MinInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Wang HaiboInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Shi YouyangInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Tadashi HisamitsuDepartment of Physiology, School of Medicine, Showa University, Tokyo, Japan.
Ishikawa ShintaroDepartment of Physiology, School of Medicine, Showa University, Tokyo, Japan.
Guo ShiyuDepartment of Physiology, School of Medicine, Showa University, Tokyo, Japan.
Liu YanqingInstitution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Yangzhou University · CNShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypervascularity is one of the main characteristics of hepatocellular carcinoma (HCC). However, the mechanisms of angiogenesis in HCC remain controversial. In this study, we investigate the role of Notch1 in angiogenesis of HCC. We found that Notch1 expression was correlated with formation of vasculogenic mimicry (VM) and expression of biomarkers of epithelial-to-mesenchymal transition (EMT) in the tumor specimens. Two HCC cell lines, HepG2 and MHCC97-H, with low and high Notch1 expression, respectively, were used to study the mechanism of VM formation both in vitro and in vivo. It was found that MHCC97-H cells, but not HepG2 cells form VM when they grow on matrigel in vitro. HepG2 cells gained the power of forming VM when they were overexpressed with Notch1, while knockdown Notch1 expression in MHCC97-H cells led to the loss of VM forming ability of the cells. Similar results were found in in vivo study. High expression of Notch1 in HepG2 promoted xenograft growth in nude mice, with abundant VM formation in the tumor samples. Moreover, we observed Notch1 was associated with the EMT and malignant behavior of hepatocellular carcinoma by analyzing clinical specimens, models for in vitro and in vivo experiments. HepG2 presented EMT phenomenon when induced by TGF-β1, accompanied by Notch1 activation while MHCC97-H with knockdown of Notch1 lost the responsiveness to TGF-β1 induction. Our results suggest that Notch1 promotes HCC progression through activating EMT pathway and forming VM. Our results will guide targeting Notch1 in new drug development.

Indexed as

AnimalsCarcinoma, HepatocellularCell Line, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMiceMice, NudeNeoplasm TransplantationNeovascularization, PathologicReceptor, Notch1Up-RegulationNOTCH1 protein, humanReceptor, Notch1epithelial-to-mesenchymal transition (EMT)hepatocellular carcinoma (HCC)Notch1vasculogenic mimicry (VM)

Identifiers

PMID27705934
PMCPMC5356819
OpenAlexW2525610905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.